EGFR and non-small cell lung carcinoma: Major restrains of molecular targeted therapy are: i) the redundancy of signaling pathways in eukaryotic cells that impairs the capacity of single target inhibition to produce persistent tumour suppression, even in cases of demonstrated “target addiction” as for the activating mutations in the Epidermal Growth Factor receptor (EGFR) in non-small cell lung cancer (NSCLC), occurring in non smoking or light smoking individuals [41]; ii) the intrinsic complexity of cancer cells that make highly problematic the identification of the effective target in most malignancies [42].